Skip to main content

AGC completes large-scale line

AGC’s subsidiary AGC Wakasa Chemicals has held a formal ceremony for the completion of a large-scale, multi-purpose production line at its Kaminaka plant in Japan. Scheduled to begin operations in Q1 204, the new line will add 50% to AGC Wasaka’s capacity for CDMO services for the agrochemicals and pharmaceuticals sector.

AGC to expand in Spain

Japan’s AGC has announced plans for a new, 7,500 m2 building at the site of its AGC Pharma Chemicals Europe CDMO operation in Spain. Costing about $100 million, this is scheduled to begin operation in 1H 2024 and will add 30% to the site’s capacity. This comes on top of a 30% increase in capacity announced in April 2020.

CDMO expansion for AGC

AGC is to expand the production lines of its AGC Wakasa Chemicals subsidiary at the Kaminaka plant in Japan’s Fukui prefecture. The amount involved was not disclosed but the expansion, due to start operation in Q1 2024, will increase AGC Wakasa Chemicals’ manufacturing capacity by 50%, with more potentially to come.

AGC plays ‘Chopin’

Japan’s AGC has announced that it has developed an integrated operation and quality management system for chemical plants called ‘Chopin’. This follows test runs at a fluorinated resin ring plant at the Chiba site in 2019, which reduced working time by more than 11 hours/day and generated savings of Y100 million through more stable operation.

More CDMOs in COVID-19 deals

The ongoing race to develop the first effective vaccines for the treatment of COVID-19 continues to generate manufacturing and development agreements between pharmaceutical giants, biotechs and CDMOs.

Most recently, Sterling Pharma Solutions agreed to carry out final purification of drug product for Moleculin Biotech’s WP1122 drug candidate from its site in Cary, North Carolina. Moleculin is about to submit an IND for this to the FDA and wanted a reliable source of supply in the US.

AGC expands Spanish site

AGC has announced plans to expand its CDMO subsidiary, AGC Pharma Chemicals Europe. As well as adding 30% to the capacity of its production facilities by May 2022, this will see the addition of a new micronisation facility and a new R&D facility, which is due to begin operation in March 2021. The plant, near Barcelona, was originally known as Malgrat Pharma Chemicals.

Subscribe to agc